ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
Aevi Genomic Medicine Inc
0.1659
+0.0000
成交量:
- -
成交额:
- -
市值:
1,289.27万
市盈率:
-0.56
高:
0.1659
开:
0.1659
低:
0.1659
收:
0.1659
数据加载中...
总览
公司
新闻
公告
公司资料
公司名字:
Aevi Genomic Medicine Inc
交易所:
NASDAQ
成立时间:
- -
员工人数:
- -
公司地址:
- -
官网:
http://www.medgenics.com
邮编:
- -
电话:
- -
传真:
- -
简介:
Medgenics, Inc.于2000年1月27日在特拉华州成立,其全资附属公司 Medgenics Medical(以色列)Limited在以色列国依法成立。该公司从事于医疗技术和治疗,开发专有创新技术平台,为一千多亿美元的蛋白质疗法市场提供新的疗法。其BiopumpTM平台技术将患者的真皮组织转成可形成蛋白质的“生物泵”,以在患者体内持续生产治疗性蛋白质。当植入患者的皮下组织时,可以提供数月的蛋白疗法,而不需要一系列频繁注射。其Biopump平台技术已被验证可以使用EPODURETM为贫血治疗提供促红细胞生成素(EPO),且贫血患者的血红蛋白显示出高水平和稳定性,而这些患者大都是在I/II期用药达6个月及以上的慢性肾脏病(CKD)患者,且试验结果显示其中一个病人在长达36月内稳定在高血红蛋白水平。其Biopump是组织微泵(MO),形成于患者的牙签大小的皮肤组织,可以产生并分泌特定的蛋白质。该公司已经开发出名为DermaVac的专有设备,以方便微泵的去除和Biopumps的植入。
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/GNMX/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GNMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNMX\",,,,,undefined,":{"symbol":"GNMX","market":"US","secType":"STK","nameCN":"Aevi Genomic Medicine Inc","latestPrice":0.1659,"timestamp":1580763600000,"preClose":0.1659,"halted":4,"volume":0,"delay":0,"floatShares":67896168,"shares":77713782,"eps":-0.295664,"marketStatus":"退市","change":0,"latestTime":"05-01 16:18:30 EDT","open":0.1659,"high":0.1659,"low":0.1659,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.295664,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1746144000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1302235200000,"exchange":"NASDAQ","adjPreClose":0.1659,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNMX\",,,,,undefined,":{"symbol":"GNMX","floatShares":67896168,"roa":"-104.54%","roe":"-372.06%","lyrEps":-0.501371,"shares":77713782,"dividePrice":0,"high":0.1659,"amplitude":0,"preClose":0.1659,"low":0.1659,"week52Low":0.11,"pbRate":"38.83","week52High":0.347,"institutionHeld":0,"latestPrice":0.1659,"eps":-0.295664,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.295664,"open":0.1659},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.medgenics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0357},{"period":"1month","weight":-0.0087},{"period":"3month","weight":-0.0835},{"period":"6month","weight":-0.0289},{"period":"1year","weight":0.1047},{"period":"ytd","weight":-0.0538}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Medgenics, Inc.于2000年1月27日在特拉华州成立,其全资附属公司 Medgenics Medical(以色列)Limited在以色列国依法成立。该公司从事于医疗技术和治疗,开发专有创新技术平台,为一千多亿美元的蛋白质疗法市场提供新的疗法。其BiopumpTM平台技术将患者的真皮组织转成可形成蛋白质的“生物泵”,以在患者体内持续生产治疗性蛋白质。当植入患者的皮下组织时,可以提供数月的蛋白疗法,而不需要一系列频繁注射。其Biopump平台技术已被验证可以使用EPODURETM为贫血治疗提供促红细胞生成素(EPO),且贫血患者的血红蛋白显示出高水平和稳定性,而这些患者大都是在I/II期用药达6个月及以上的慢性肾脏病(CKD)患者,且试验结果显示其中一个病人在长达36月内稳定在高血红蛋白水平。其Biopump是组织微泵(MO),形成于患者的牙签大小的皮肤组织,可以产生并分泌特定的蛋白质。该公司已经开发出名为DermaVac的专有设备,以方便微泵的去除和Biopumps的植入。","exchange":"NASDAQ","name":"Aevi Genomic Medicine Inc","nameEN":"Aevi Genomic Medicine Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"GNMX\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GNMX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-14","symbol":"GNMX","fiscalQuarterEnding":"2019/09","expectedEps":-0.05,"name":null,"time":"","type":"earning","dateTimestamp":1573707600000,"reportTimeType":"","actualEps":-0.06},{"market":"US","date":"2019-08-13","symbol":"GNMX","fiscalQuarterEnding":"2019/06","expectedEps":-0.1,"name":null,"time":"","type":"earning","dateTimestamp":1565668800000,"reportTimeType":"","actualEps":-0.06},{"market":"US","date":"2019-05-14","symbol":"GNMX","fiscalQuarterEnding":"2019/03","expectedEps":-0.1,"name":null,"time":"","type":"earning","dateTimestamp":1557806400000,"reportTimeType":"","actualEps":-0.07},{"market":"US","date":"2018-11-01","symbol":"GNMX","fiscalQuarterEnding":"2018/09","expectedEps":-0.16,"name":null,"time":"","type":"earning","dateTimestamp":1541044800000,"reportTimeType":"","actualEps":-0.12},{"market":"US","date":"2018-08-02","symbol":"GNMX","fiscalQuarterEnding":"2018/06","expectedEps":-0.15,"name":null,"time":"","type":"earning","dateTimestamp":1533182400000,"reportTimeType":"","actualEps":-0.14}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GNMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GNMX\",market:\"US\",delay:false,,,undefined,":{}}}